Piperidine → 2-[1-(5-Methoxy-3-piperidin-1-yl-pyrazin-2-ylmethyl)-1H-imidazol-2-yl]-pyrimidine

HRID 1609854ノート

反応式

HRID 1609854 の反応式
Cl[C:2]1[C:3]([CH2:10][N:11]2[CH:15]=[CH:14][N:13]=[C:12]2[C:16]2[N:21]=[CH:20][CH:19]=[CH:18][N:17]=2)=[N:4][CH:5]=[C:6]([O:8][CH3:9])[N:7]=1.[NH:22]1[CH2:27][CH2:26][CH2:25][CH2:24][CH2:23]1>>[CH3:9][O:8][C:6]1[N:7]=[C:2]([N:22]2[CH2:27][CH2:26][CH2:25][CH2:24][CH2:23]2)[C:3]([CH2:10][N:11]2[CH:15]=[CH:14][N:13]=[C:12]2[C:16]2[N:21]=[CH:20][CH:19]=[CH:18][N:17]=2)=[N:4][CH:5]=1

参加物

3

反応物 2

HCID 8082PiperidineHCID 103575922-[1-(3-chloro-5-methoxy-pyrazin-2-ylmethyl)-1H-imidazol-2-yl]-pyrimidine

生成物 1

HCID 102473812-[1-(5-Methoxy-3-piperidin-1-yl-pyrazin-2-ylmethyl)-1H-imidazol-2-yl]-pyrimidine

反応条件

温度
110 °C

実験手順

A mixture of 2-[1-(3-chloro-5-methoxy-pyrazin-2-ylmethyl)-1H-imidazol-2-yl]-pyrimidine (30 mg, 0.099 mmol), and piperidine (1 mL) is heated at 110° C. in a sealed tube for 1 hour. On cooling, the volatile materials are removed in vacuo and the residue is purified by PTLC (silica gel; 10% MeOH in DCM) to give 35 mg of 2-[1-(5-Methoxy-3-piperidin-1-yl-pyrazin-2-ylmethyl)-1H-imidazol-2-yl]-pyrimidine. 1H NMR (CDCl3) 8.74 (d, 2H), 7.62 (s, 1H), 7.21 s, 1H), 7.08–7.15 (m, 2H), 5.86 (s, 2H), 3.87 (s, 3H), 3.06–3.15 (m, 4H), 1.52–1.66 (m, 6H).

後処理

  1. temperatureOn cooling
  2. customthe volatile materials are removed in vacuo
  3. customthe residue is purified by PTLC (silica gel; 10% MeOH in DCM)

出典と根拠

ORDレコード
ord-e615be6038e64aafaadb252d181f0ce0
出典データセット
uspto-grants-2006_01
特許番号
US06982268B2

反応ノート

読み込み中…